ImageneBio reports Q3 cash position of $142.6 million and increased R&D expenses
I'm PortAI, I can summarize articles.
ImageneBio Inc. reported a Q3 cash position of $142.6 million, significantly up from $12.1 million at the end of 2024, following its merger with Ikena Oncology and a $75 million private placement. R&D expenses rose to $15.6 million, while general and administrative expenses increased to $11 million. The net loss for the quarter was $24.8 million, compared to $3.2 million in the previous year, largely due to merger-related costs. The company also announced protocol amendments for its Phase 2b ADAPTIVE study and upcoming data presentations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments